Participates in the initial step of the glucosylceramide- based glycosphingolipid/GSL synthetic pathway at the cytosolic surface of the Golgi.
Drugs that act on it: 4
Approved: 2
In phases 1 to 3: 2
Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on UGCG, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Ceramide glucosyltransferase inhibitor.
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2063, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q16739, CC BY 4.0) and disease associations are from Open Targets (CC0).ChEMBL and Open Targets
Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.